Drug Development in Gastric Cancer: Are We at an Inflection Point?

Gastric cancer drug development has long been thwarted by the challenges of identifying effective targets and developing drugs against the backdrop of the cancer’s inherent tumor heterogeneity.1 Recently, however, advances in our understanding of the molecular underpinnings of gastric cancer and the discovery of actionable biomarkers have led to substantial progress in drug development, leading to improved survival in gastric cancer. …

ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor

SAN DIEGO and SHANGHAI, May 5, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States. MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in …

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced positive monotherapy dose escalation data for its investigational, highly selective and potent pan-RAF inhibitor, exarafenib, from Part A1 of its ongoing global Phase 1 KN-8701 clinical trial. These results will be featured in an oral presentation today …

MatTek and NEXT Oncology Announce Licensing Agreement

The Boston-based biotech company will use an inventory of patient-derived cancer cells to develop new lab-grown tumor models to accelerate and refine oncology research, and provide more targeted treatments for cancer patients. [For immediate release: Ashland, MA and San Antonio, TX, April 17, 2023] – MatTek Life Sciences and NEXT Oncology jointly announced today a licensing agreement that will have MatTek turn NEXT Oncology’s …

Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors

The first patient has been dosed with DK210 in a first-in-human, phase 1 clinical trial (NCT05704985) for patients with EGFR-expressing advanced solid tumors.1 “The Diakine™ platform combines the potent anti-cancer function of interleukin-2 [IL-2] with the inflammation-controlling function of interleukin-10 and targets these cytokines to the tumor,” Alexander Spira, MD, PhD, FACP, co-director of the Virginia Cancer Specialists Research Institute, told …

Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an advisory board, comprised of Dr. John Lambert and Dr. Anthony Tolcher, to prioritize selection of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities. Read the …

Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records (EHR) to the sponsor’s electronic data capture systems (EDC). Through the partnership, Syneos Health …

ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM

Paris (France), January 25th, 2023 – 6pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative tumor specific drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today provides an update on the clinical development program of its first-in-class drug candidate AsiDNATM. Onxeo activated its first …

Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

SAN FRANCISCO, November 1, 2022 – Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced that the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an …

Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board

Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission to develop next-generation multifunctional precision immunotherapies for cancer – October 18, 2022 — SAN DIEGO, California & BASEL, Switzerland — Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein …